vadimezan has been researched along with Hypoxia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Busk, M; Horsman, MR; Iversen, AB | 1 |
| Thorpe, PE | 1 |
1 review(s) available for vadimezan and Hypoxia
| Article | Year |
|---|---|
Vascular targeting agents as cancer therapeutics.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Cell Division; Clinical Trials as Topic; Diphosphates; Genetic Therapy; Humans; Hypoxia; Immunotoxins; Ligands; Models, Biological; Necrosis; Neoplasms; Organophosphorus Compounds; Peptides; Radioimmunotherapy; Stilbenes; Time Factors; Up-Regulation; Xanthones | 2004 |
1 other study(ies) available for vadimezan and Hypoxia
| Article | Year |
|---|---|
Induction of hypoxia by vascular disrupting agents and the significance for their combination with radiation therapy.
Topics: Animals; Antineoplastic Agents; Blood Vessels; Chemoradiotherapy; Diphosphates; Female; Flavonoids; Hypoxia; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C3H; Oxygen; Stilbenes; X-Ray Therapy; Xanthones | 2013 |